Taking into account that IGF2BP3 sustains IGF1R expression as well [162], we can speculate that co-targeting the IGF axis and CXCR4 in Ewing sarcoma cells expressing high levels of IGF2BP3 might represent a valuable therapeutic option. The gene discussed is IGF1; the disease is Ewing sarcoma.